@Lord_of_Biotech This makes me remember Freeline Therapeutics, very similiar setup with the same backup (syncona) , guess syncona pressuring them - is it a buy for you at these levels ?
@Lord_of_Biotech Thanks a lot , I really appreciate the answer and I also think $GLTO is a very good C/R ratio play. I really look forward to your other similiar plays
@MassimoSTU I think it’s important that their share structure is clean and they have some assets on top for a CVR and/or outlicensing against some upfront. With that market cap they do not need much cash inflow to bring shareholders a good payout.
@Lord_of_Biotech With a market cap of 15 and cash of 23 and they somehow spending 1 mln per one cut person if they fire the rest they would end up at 19 mln , plus the assets. Is this correct ?
@Lord_of_Biotech Thanks for pointing out, to estimate a floor what would be the range for liquidation costs ? So we can deduct it from the 0.12 cents ?
@monaco_biotech Company is now trading at cash 433 mln in equity - 100 mln in wind down costs = 333 mln net cash value
Current sp: 5$ * 67 mln shares = 335 mln
@monaco_biotech Are you in this one ?
I think this is very positive indicator for there full approval in the us and now they got a second market europe